Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Glycopeptide Antibiotics Market Expected to Be in 2029?
The market size for glycopeptide antibiotics has seen substantial growth in the past years. The market is projected to increase from $3.54 billion in 2024 to $3.78 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. Factors such as increased antibiotic resistance, the surge in infectious diseases, governmental policies, escalated healthcare expenditures, and the global spread of infectious diseases have contributed to this growth during the historical period.
Anticipations are high for the glycopeptide antibiotics market, with solid growth projected in the coming years. The market is expected to expand to “$5.38 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this forecasted growth include the emergence of infectious diseases, growth in the aging population, ongoing challenges with antibiotic resistance, investments in research and development, and expansion of the healthcare infrastructure. Notable trends for the forecast period include rising antibiotic resistance, developments in R&D, global health crises spurring demand, partnerships for antibiotic stewardship, and market growth in emerging economies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
What Are The Contributors To Demand In The Glycopeptide Antibiotics Market?
The escalating incidence of cancer and infectious diseases is projected to fuel the expansion of the glycopeptide antibiotics market in the future. Cancer is a disease characterized by the abnormal and uncontrollable multiplication and spread of certain body cells, while infectious diseases are caused by various organisms, including bacteria, viruses, fungi, or parasites. Glycopeptide antibiotics find application in handling numerous infectious conditions caused by bacteria such as methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus, which show resistance to beta-lactams and other antibiotics. For cancer patients, glycopeptide antibiotics enhance the anticancer effects of radiotherapy by eradicating not just the targeted cancer cells, but also far-reaching cancer cells within the body. For example, the American Cancer Society, a non-profit health organization based in the U.S. dedicated to eliminating cancer, reported 1.9 million new cancer cases and 609,360 cancer-related deaths in 2022, which equals to approximately 1,670 deaths per day. As such, the surge in cancer and infectious disease instances is anticipated to further facilitate the growth of the glycopeptide antibiotics market.
What Segmentation Categories Are Included In The Glycopeptide Antibiotics Market Analysis?
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Linezolid, Daptomycin, Other Glycopeptide and Lipoglycopeptide Antibiotics
4o
What Are The Leading Trends And Opportunities In The Glycopeptide Antibiotics Sector?
The focus on product innovation is an emerging trend in the glycopeptide antibiotics market. Major market players are concentrating on creating innovative products to affirm their market position. For example, Leiden University, a research institution based in the Netherlands, unveiled new versions of the antibiotic vancomycin in October 2022. This was achieved by attaching a group of molecules to the structure of an existing vancomycin molecule. This newly innovated version of vancomycin is up to a thousand times more potent against gram-positive bacteria compared to the original form and has lesser nephrotoxicity compared to the commercially used polymyxin antibiotics. This innovation was necessitated due to the limitations of vancomycin, which only works effectively against gram-positive strains and is incapable of penetrating the outer membrane of gram-negative bacteria.
Who Are The Top-Ranked Companies In The Glycopeptide Antibiotics Market Today?
Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
How Is Glycopeptide Antibiotics Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9444&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model